Zhou Xuyan, Lian Haiying, Li Hongpeng, Fan Meiling, Xu Wei, Jin Ye
School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China.
Gynecology Department, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Front Pharmacol. 2022 Dec 16;13:1065793. doi: 10.3389/fphar.2022.1065793. eCollection 2022.
Immunotherapy is an emerging method for the treatment of cervical cancer and is more effective than surgery and radiotherapy, especially for recurrent cervical cancer. However, immunotherapy is limited by adverse effects in clinical practice. In recent years, nanotechnology has been widely used for tumor diagnosis, drug delivery, and targeted therapy. In the setting of cervical cancer, nanotechnology can be used to actively or passively target immunotherapeutic agents to tumor sites, thereby enhancing local drug delivery, reducing drug adverse effects, achieving immunomodulation, improving the tumor immune microenvironment, and optimizing treatment efficacy. In this review, we highlight the current status of therapeutic vaccines and adoptive cell therapy in cervical cancer immunotherapy, as well as the application of lipid carriers, polymeric nanoparticles, inorganic nanoparticles, and exosomes in this context.
免疫疗法是一种新兴的宫颈癌治疗方法,比手术和放疗更有效,尤其适用于复发性宫颈癌。然而,免疫疗法在临床实践中受到副作用的限制。近年来,纳米技术已广泛应用于肿瘤诊断、药物递送和靶向治疗。在宫颈癌的治疗中,纳米技术可用于将免疫治疗药物主动或被动靶向肿瘤部位,从而增强局部药物递送、减少药物不良反应、实现免疫调节、改善肿瘤免疫微环境并优化治疗效果。在本综述中,我们重点介绍了治疗性疫苗和过继性细胞疗法在宫颈癌免疫治疗中的现状,以及脂质载体、聚合物纳米颗粒、无机纳米颗粒和外泌体在这方面的应用。